What is needed to guide testing for anorectal and pharyngeal  and  in women and men? Evidence and opinion by unknown
DEBATE Open Access
What is needed to guide testing for
anorectal and pharyngeal Chlamydia
trachomatis and Neisseria gonorrhoeae in
women and men? Evidence and opinion
Nicole H. T. M. Dukers-Muijrers1,2*†, Julius Schachter3†, Genevieve A. F. S. van Liere1,2, Petra F. G. Wolffs2
and Christian J. P. A. Hoebe1,2
Abstract
Background: Anorectal and pharyngeal infections with Chlamydia trachomatis (CT) and Neisseria gonorrheae (NG) are
commonly observed in men who have sex with men (MSM). There is increasing evidence that such infections at extra-
genital sites are also common in women. In both sexes, these infections are largely overlooked as they are not
routinely tested for in regular care. Testing based on sexual behavior or symptoms would only detect half of these
extra-genital infections. This paper elucidates the differences and similarities between women and MSM, regarding the
epidemiology of extra-genital CT and NG. It discusses the clinical and public health impact of untested extra-genital
infections, how this may impact management strategies, and thereby identifies key research areas.
Discussion: Extra-genital CT is as common in women as it is in MSM; NG in women is as common at their extra-
genital sites as it is at their genital sites. The substantial numbers of extra-genital CT and NG being missed in women
and MSM indicate a need to test and treat more patients and perhaps different choices in treatment and partner
management strategies. Doing so will likely contribute to reduced morbidity and transmission in both sexes. However,
in our opinion, it is clear that there are several knowledge gaps in understanding the clinical and public health impact
of extra-genital CT and NG. Key research areas that need to be addressed concern associated morbidity (anorectal and
reproductive morbidity due to extra-genital infections), ‘the best’ management strategies, including testing and
treatment for extra-genital CT, extra-genital treatment resistance, transmission probabilities between partners and
between anatomic sites in a woman, and impact on transmission of other infections. Data are also lacking on cost-
effectiveness of pharyngeal testing, and of NG testing and anorectal CT testing in women. Gaps in the management of
extra-genital CT and NG may also apply for other STIs, such Mycoplasma genitalium.
Summary: Current management strategies, including testing, to address extra-genital CT and NG in both sexes are
suboptimal. Comparative data on several identified key themes in women and MSM are lacking and urgently needed
to guide better management of extra-genital infections.
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Background
It is a continuous challenge to control the spread of
sexually transmitted infections (STIs). Chlamydia
trachomatis (CT) and Neisseria gonorrhoeae (NG)
are sexually transmissible bacteria that may result in
serious complications such as pelvic inflammatory
disease, infertility and ectopic pregnancy in women,
and epididymitis in men and play an important role
in enhancing HIV transmission [1, 2]. The Centers
for Disease Control and Prevention (CDC) reported
about 1.4 million new CT infections in 2013 and
numbers are still increasing each year [3]. In Europe,
the number of CT infections is increasing with more
than 250 000 new cases reported each year [4].
The use of highly sensitive and specific laboratory
assays, i.e. nucleic acid amplification tests (NAAT),
has revealed the frequent presence of CT and NG at
extra-genital sites. Infections at extra-genital sites are
common in both men who have sex with men
(MSM) and women. In MSM, this led to specific
control guidelines, including expanded testing [5–9].
In women, such guidelines are beginning to emerge.
However, the occurrence of extra-genital infections
also has led to international debate on the (need for)
control of such infections by testing and treatment.
This paper addresses the state of the art in extra-genital
NG and CT epidemiology, elucidating the differences and
similarities in women versus MSM, argues how this may
impact control strategies, and identifies the knowledge
gaps to address these issues to guide testing.
Epidemiology of extra-genital STI in women and MSM
To provide an overview on state-of-the-art on the preva-
lence and anatomic site distribution of CT and NG infec-
tions in women, we have reviewed the literature focusing
on including studies (in English) in women describing
anorectal and/or pharyngeal CT and NG infections de-
tected using NAATs. We conducted a Medline search (last
update 8 June 2015) using the terms: (‘women or woman
or female’) and (‘chlamydia’, ‘gonorrhea’ or ‘gonorrhoeae’).
These terms were used in combination with (‘anorectal or
rectal or anal’) or (‘oropharyngeal or pharyngeal or oral’)
or (‘extra-genital’). Additionally, relevant results on ano-
rectal CT that could not directly be retrieved from these
papers were kindly provided by the authors of these stud-
ies. We compared results to findings in several key papers
in MSM from different countries and using NAAT. Be-
cause there is an abundant literature on extra-genital in-
fections in MSM a literature search was deemed not
necessary.
Prevalence
Prevalence, which is defined here as the proportion of
the study population that tested positive, has so far for
women only been assessed in clinic-based populations.
The observed prevalence ranges of extra-genital CT as
detected by NAAT are notably similar between women
[10–32] and MSM [11, 18, 24, 25, 32–39], ranging be-
tween 1 and 3 % for pharyngeal CT and 1–18 % for ano-
rectal CT (see Table 1). Of note, MSM who define
themselves as being heterosexual (e.g. male swingers)
have appreciable numbers of anorectal infections as well
[11]. Pharyngeal CT and NG prevalences in heterosexual
men are similar to that seen in women (e.g. [11, 28]).
Overall however, data in heterosexual men are scarce.
Most studies on anorectal CT (see Table 2) have in-
cluded women tested on indication of receptive anal
intercourse (RAI). Few studies reported systematic test-
ing of all women, i.e. testing irrespective of reported be-
havior or symptoms [10–12, 27]. Most studies were
done in women attending care services; one study re-
ported on women testing by self-triage via the Internet
[14] and another study reported on women in the ‘open
population’ reached via friends in their social network
[31]. Comparable prevalence ranges in the tested popu-
lations were reported across studies. It was notable that
some geographic variation might be present. Excluding
two studies that tested on indication of genital CT, prev-
alences of anorectal CT in most studies in Canada
(11.7–13.5 % ) or US (5.1–27.3 % ) appeared even higher
than that of most studies in Europe (5.6–12.5 % ). Still,
we need more representative data from future studies
with less selected populations to be able to compare
prevalence rates (and associated factors) in women. Such
population-based studies are feasible given the high ac-
ceptance of self-collection methods for testing.
In MSM in the Netherlands and Germany, lympho-
granuloma venereum (LGV) serovars comprised 2–16 %
of CT positive anorectal samples and were also found in
the pharynx and urethra [40, 41]. In women, LGV is very
unusual, although systematic assessment of LGV in
women is scarce [42].
The prevalence of extra-genital NG reflects the well
known disparity between MSM and women (see Table 1).
The occurrence of NG is at all anatomic sites substan-
tially less frequent in women; women show NG
Table 1 Prevalence of extra-genital Chlamydia trachomatis (CT)
and Neisseria gonorrhoeae (NG) in women and in men who have
sex with men (ref.: [10–32] for women and [11, 18, 24, 25, 32–
41] for MSM)
Women Men who have sex with men
CT NG CT LGV (of CT+) NG
Pharyngeal 1–3 % 1–2 % 1–3 % 9–16 % 4–12 %
Anorectal 7–17 % 0–3 % 1–18 % 2–16 % 6–21 %
Genital 5–13 % 1–2 % 3–8 % 2 % 3–11 %
LGV Lymphomgranuloma Venereum
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Table 2 Overview of studies that include anorectal Chlamydia trachomatis (CT) nucleic acid amplification testing in women by routine systematic testing or selective testing on
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prevalences up to 3 %, while prevalences in MSM are up
to 21 % [10–18, 20–25, 28, 29, 33, 34, 36–39].
Concurrence of infections at extra-genital and genital sites
There are notable differences between women and MSM
in how frequent an infection at the extra-genital site oc-
curs together with infection at the genital site. A women
with an anorectal infection usually also has a concurrent
genital infection. The studies presented in Table 2 show
that in women, between 5 and 29 % of the anorectal CT
infections are single site anorectal infections, i.e. without
a genital infection.
Among the women who have a CT or NG infection at
the genital site (which is routinely tested for in care), a
substantial part have a concurrent infection at the ano-
rectal site: between 33 % (i.e. [12]) and 83 % (i.e. [11]) of
women with genital CT also were found to have an ano-
rectal CT (calculated from the studies presented in
Table 2).
In contrast, MSM with anorectal infections usually do
not have a concurrent infection at the genital site. In
MSM anorectal infections are mostly single site infections,
i.e. up to 91 % for CT and up to 70 % for NG [33–39, 43].
Still, similar to women who have a genital infection, a
large proportion of MSM who have a genital infection
may have a concurrent infection at the anorectal site: one
study of 2436 MSM in a Dutch STI clinic found anorectal
infections in about half of genitally infected MSM [43].
Pharyngeal CT prevalence is low in MSM and in
women (see Table 1), and in both sexes frequently oc-
curs in the absence of anorectal or genital CT, e.g. of
pharyngeal CT 32–44 % was single in women and 53–
85 % in MSM [18, 32, 33, 43–47]. Pharyngeal NG preva-
lence is higher in MSM than in women (see Table 1),
and also frequently occurs as a single infection in both
sexes. For example one study revealed 53 % of




Detection of extra-genital CT and NG is best done by
NAAT [7]. Such tests are highly sensitive and specific
and were shown valid and robust for extra-genital detec-
tion (e.g. [25, 29, 48, 49]). Also, self-collection of samples
in case of anorectal infections is well accepted and
feasible in both women and in men. Still, the lack of
clearance from the Food and Drug Administration
(FDA-USA regulations) and lack of a CE-IVD mark
(European regulations) for such testing, has greatly ham-
pered its use in current clinical practice [50].
The focus in current health care is not on extra-genital
testing; it has largely remained on genital testing. For ex-
ample, a laboratory surveillance from all types of health
care providers who perform CT testing in Australia
showed that only in 3 % of the test episodes was extra-
genital CT tested alongside genital CT [51]. This is fur-
ther corroborated by a study from The Netherlands
showing that GPs and gynecologists performed more CT
tests than did STI clinics, but they infrequently (<1 % )
tested for anorectal or pharyngeal CT [52]. Extra-genital
testing, when it is done, is done in the STI clinic setting,
and CT and NG are usually tested simultaneously be-
cause most commercially available NAATs detect both.
However, such extra-genital testing tends to focus on
MSM, not women, and test practices vary widely be-
tween STI clinics, even within a country [18, 34, 53].
Testing guidelines
Current international guidelines for CT and NG test-
ing [5–9] include a pharyngeal or anorectal test after
symptoms and after behavioral exposure, i.e. receptive
oral sex or receptive anal sex, respectively. Most
guidelines focus on MSM and some also include spe-
cific groups of women, such as sex workers. None of
the guidelines include women in general as a target
group. Unfortunately, the recommendation to restrict
testing to certain exposure risks has not been based
on evidence. Actual testing results show that extra-
genital testing of all people reporting extra-genital ex-
posure would still result in over half of extra-genital
infections remaining undetected in both women (see
Table 2) and in MSM who attend health care for
genital testing [11, 18, 24, 25, 32–39, 43–47]. The
prevalence of anorectal CT was consistently similar
between women reporting and not reporting (recep-
tive) anal sex, as shown in Table 2. Similar observa-
tions have been made for NG, and also in MSM.
Could the observed presence of anorectal infections
be explained by underreporting of anal sexual expos-
ure? Reporting bias is unlikely to explain a major part
as then such bias would need to be unrealistically
high and consistent across studies and countries. Bias
by using a recall period that is too short to capture
the behavioral exposure is probably more likely, given
that anal sex is usually recorded as behavior in a
given time period (usually a couple of months). Oral
and anal sex are commonly reported by women and
MSM [10, 11, 20, 26, 27, 54]. Therefore, infections
may have been acquired before the beginning of the
screening interval, and be unnoticed due to its
asymptomatic nature and lack of extra-genital testing.
It has been suggested that anorectal pathogens may
potentially be transmitted by practices that involve
contact with the anus other than penetrative anal-
genital sex (i.e. by transmission by fingers or by sex
toys), although evidence for this is inconclusive
[10, 30, 55].
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It should be noted that for anorectal infections,
transmission methods other than sex with by an in-
fected partner have been postulated. The most plaus-
ible of these in women is self-infection (auto-
inoculation). The presence of anorectal infections in
women without anal sex and the high rate of concur-
rence with infections at the genital site, fuelled the
belief that anorectal infections in women are largely
the result of self-infection. The anatomical proximity
of genital and anorectal site makes this plausible.
However, self-infection has not been confirmed by
rigorous data. Also, the observed high rates of con-
curring genital and anorectal infections in women is
predictable given the likelihood that women who have
anal sex will also have vaginal sex [54]. Possibly dif-
ferences in behavior between the women and MSM
(frequency of anal sex, number of anal sex partners,
co-practice of anal and genital intercourse) may also
drive discordance of anatomic site infections. Further,
it can be considered very unlikely that possible swab
contamination by inadequate swab handling (due to
contamination from the genital infection or the envir-
onment), would contribute much to the observed
anorectal detections [25, 56]. A different theory to ex-
plain anorectal CT detection involves the gastro-
intestinal (GI) tract as a reservoir for CT detection.
While asymptomatic CT infections have been de-
tected in the GI tract of neonates exposed at birth,
and rectal shedding has been observed in children in
trachoma endemic areas, the theory that the GI tract
could act as a reservoir in humans, for example
though oral exposure, was more recently shaped by
new observations in mice [57–59]. However, evidence
to support long term persistence of CT in the GI
tract in human adults is completely lacking.
The vast majority of extra-genital CT and NG are
asymptomatic, i.e. without oral or anorectal symptoms re-
ported [1, 2]. Even in the case for LGV, many infections in
MSM have been shown to go without symptoms [40, 41].
In fact, this is similar to genital infections, that are also
frequently asymptomatic. There is little or no evidence
that CT strains differ between anatomic sites regarding
their genotype or their pathogenic potential. In MSM,
some studies demonstrated associations between anorec-
tal NG infections, anorectal NG bacterial load and procti-
tis [35, 47, 60]. Still, it should be noted that generally
anorectal symptoms are rarely reported (<5 %) and that
most extra-genital infections are without symptoms.
Treatment
Generally, treatments recommended for extra-genital
STI do not differ from that of genital STI. For CT how-
ever, the recommended first choice treatments may dif-
fer between anorectal and genital infection. For genital
CT infection azithromycin 1-g single dose is advised.
For anorectal CT, azithromycin or doxycycline 100mg
twice daily for seven days are considered equal first line
treatments in the US. Other countries (Netherlands,
Australia, and UK in their most recent draft of guide-
lines) now have doxycycline as first choice in anorectal
CT [5–9]. These new recommendations reflect concern
that azithromycin efficacy for anorectal infections may
be less than what was expected. Yet, neither recommen-
dation, i.e. to use the treatments as equal first line treat-
ments or prefer the one over the other, stems from
robust studies showing equivalent or different efficacy at
different anatomic sites. These recommendations are ex-
trapolated from solid evidence supporting the efficacy of
these regimens for genital CT treatment and from clin-
ical experience and expert consultation [61–63]. The
internationally recommended treatment regimen for
LGV is a 3-week course of oral doxycycline 100 mg
twice daily [55]. Genital and extra-genital NG can be
treated with ceftriaxone or with ciprofloxacin when cef-
triaxone is contraindicated and strains show no cipro-
floxacin resistance [5–9].
Discussion
Routine extra-genital testing for CT and NG is pos-
sible using NAAT and minimally invasive sampling
methods. However, extra-genital infections are still
not routinely tested for in MSM and testing is even
less common in women. As these infections are
mostly asymptomatic, they are frequently overlooked
in health care. Extra-genital infections, in women es-
pecially anorectal CT, are common and testing based
on exposure or symptoms misses over half of these
extra-genital infections. More testing in women and
in MSM would identify many more extra-genital in-
fections. But, what are the implications for clinical
practice of testing more? Untreated infections might
continue to cause complications and potentially drive
further transmission. Still, what are the public health
gains of testing more? Should control strategies be
different for MSM and women? Some answers to
these questions will provide us with more insight into
what is needed to guide extra-genital testing in MSM
and in women.
What are implications for clinical practice of managing
extra-genital CT and NG?
Testing more patients and testing more samples per patient
A substantial proportion of infected individuals do
not attend a testing facility for testing or retesting,
and are obviously missed, hence remain untreated
[64]. Even so, when people do attend care, they are in
most cases tested at genital sites only. Addressing
currently hidden CT and NG by extra-genital testing
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of more persons would reveal many more extra-
genital infections. Several approaches to increase test-
ing coverage for genital and anorectal infections have
been evaluated and found feasible. These include
using self-collected samples at home, and using auto-
mated e-health programs [14, 31, 65, 66].
Of patients who have an anorectal infection, women
frequently have a concurrent infection at the genital site
while MSM frequently do not have a concurrent genital
infection. This implies that adding a extra-genital test to
routine genital testing would reveal much more add-
itional infected individual MSM than it would for
women, even when the prevalence is similar (such as in
anorectal CT). This also implies that to detect large part
of extra-genital infections in women we could just test
women with genital infections. A strategy to achieve
this, without having to ask the women to come back for
extra-genital testing, could be to directly take a extra-
genital sample at the routine genital STI testing visit,
but to only test the extra-genital specimen from women
who tested positive for their genital infection. In such
case, fewer extra-genital laboratory tests would have to
be performed compared to routine testing of both speci-
mens in women, perhaps reducing costs. Yet, such
phased testing strategy would also demand more com-
plex laboratory logistics and increase time to return test
results. Using this strategy implies there is a reason to
detect the extra-genital infection in a women who will
be treated because of her genital infection (different
treatment regimen or different partner management
needed?). Also, such phased testing strategy would not
detect the single site extra-genital infections that still
will remain undiagnosed and untreated. Another testing
strategy potentially reducing costs is to test pooled mul-
tiple site samples. Such approach precludes feedback on
the anatomic site(s) where the infection(s) occurs pre-
cluding treatment guidance, and its effectiveness needs
to be further explored.
More information on the clinical and public health
impact is needed to decide what would be the opti-
mal cost-effective algorithm for testing. This clinical
and public health impact of leaving extra-genital in-
fections untested may be different between the two
sexes. This is because the co-occurrence of infections
at multiple anatomic sites differs between MSM and
women and may impact the need for additional man-
agement strategies. The clinical and public health im-
pact also is dependent on the (yet unknown) role of
extra-genital infections in morbidity and transmission.
Further insight on these issues is essential to know
how the additional costs of testing extra-genital sam-
ples and managing more identified positive cases bal-
ances the costs avoided by reducing spread and
morbidity due to extra-genital testing.
Making different treatment choices
If treatment for genital infections is also adequate for
extra-genital infections, then part of the extra-genital
CT and NG would be ‘inadvertently treated’ by treating
the infection at the genital site (that is usually routinely
screened). This would most frequently apply to anorectal
infections in women, as these usually co-occur with a
genital infection, reducing the negative consequences (in
terms of morbidity and transmission) of leaving anorec-
tal CT and NG infections in women untested. However,
this scenario may not be true for anorectal CT. There
are reports suggesting that doxycycline is a better treat-
ment for anorectal CT than is azithromycin [61–63]. If a
clinician knew the patient also had an anorectal CT, a
different treatment choice might be made. At the mo-
ment, we lack thorough studies to decide what is the
best treatment for anorectal CT. Restrictions in financial
means for extra-genital testing has led some clinicians to
taking a pragmatic approach by directly treating genital
CT positive patients with doxycycline, assuming this will
treat a potential concurrent anorectal infection better
than when using azithromycin. Still, the strategy to use
doxycycline in anorectal CT is not based on solid evi-
dence. Such strategy is also limited by the higher non-
compliance rates seen with doxycycline use because of
its longer treatment duration [67]. Until we better
understand the effectiveness of anorectal CT treatment
regimens, the impact of not testing for anorectal CT in
women is difficult to assess. Well designed randomized
controlled trials on this topic are urgently needed.
In MSM, an additional contributing factor to increas-
ing the adverse consequences of an untested extra-
genital CT, is the occurrence of LGV. LGV prevalence is
low, and there are marked differences in geographic dis-
tribution, but it requires additional and different testing
and treatment.
Managing so far undetected treatment resistance
The introduction of NG treatment resistant strains poses
a challenge for its management [68]. So far, there are no
reports that its occurrence is different for genital or
extra-genital NG, although it has been suggested that
pharyngeal NG may act as a reservoir for resistance [69].
Not (appropriately) treating extra-genital NG may in-
crease the spread of resistant NG in the population, es-
pecially in MSM who show a higher prevalence than
women. Mathematical modeling suggested that the most
effective control strategy for treatment resistant NG is
by following up treated infections to re-treat failures, ra-
ther than just testing and treating more patients [70].
This could equally apply for extra-genital infections.
For CT, there is yet no evidence of homotypic anti-
microbial resistance [71]. Still, our understanding is lim-
ited as testing for antimicrobial resistance for CT is not
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routinely available, although whole genome sequencing
provides new opportunities [72].
Making more customized patient and partner management
choices
Management strategies such as re-testing, partner notifi-
cation and expedited or accelerated partner treatment
have been shown to be highly effective strategies to pre-
vent relatively high numbers of CT and NG [73]. Part-
ners of positive patients and previously tested positive
patients have a greater risk to also test positive. Treat-
ment of the sexual partners of positive cases is therefore
recommended (partner-notification) and infected pa-
tients themselves are advised to be re-tested between
3–12 months post-treatment to detect a new CT or NG
infection [3–9]. While for CT, the usefulness of perform-
ing a test-of-cure can be seriously questioned [74, 75],
for NG, a test-of-cure may sometimes be recommended
to detect a persistent infection [3–9] and as recently
suggested, to manage treatment resistant NG [70].
Again, extra-genital infections may in part be inciden-
tally handled by the strategies deployed for a detected
genital infection. However, it is not clear whether such
incidental handling is effective for extra-genital infec-
tions. For example, partner notification may not be ap-
plied when the patient did have unprotected anal/oral
sex but unprotected genital sex was not reported and a
test-of-cure may be negative for a genital NG, while it
may be positive for (untested) anorectal or pharyngeal
NG.
It also is apparent that by not testing, a single extra-
genital infection would always be missed and none of
the treatment, retest or partner notification strategies
would be employed. Therefore, by testing and treating at
genital sites only, essential control opportunities in the
management of both female and MSM patients and their
partners are lost.
What are public health gains by managing extra-genital
CT and NG?
Avoided morbidity
Some studies in MSM linked anorectal NG to symptom-
atic proctitis, which is an inflammatory syndrome of the
distal 10–12 cm of the rectum. Some LGV strains cause
a severe proctocolitis [55]. In women, it is yet unknown
whether anorectal infections can cause anal symptoms.
Even so, the large majority of extra-genital (and genital)
infections in MSM and in women are asymptomatic and
no solid evidence is present showing that symptoms are
regularly associated with anorectal CT or pharyngeal CT
or NG infections.
Hypothetically, anorectal infections in women could
have an impact on the reproductive outcomes. This
would be if an anorectal infection could be spread to the
genital site. A recent study estimated that, when self-
infection from the anorectal site plays a role, a less ad-
equate treatment would sustain CT in a woman [76].
Thus anorectal infections would act as a reservoir (by
self-infection, or during sexual activity) for genital infec-
tions (or re-infections). This would expand the spectrum
of morbidity of anorectal infections in women, increas-
ing the negative consequences of overlooking the ano-
rectal infection. In genital CT, repeat infections have
been linked to increased reproductive morbidity – more
PID and more adverse reproductive outcomes; it is un-
known if morbidity is also linked to repeat infection with
extra-genital STI.
Avoided transmission
Pharyngeal and anorectal CT and NG are probably cap-
able of being transmitted to genital sites of a partner
[77, 78]. In women, infections may potentially be trans-
mitted from their anorectal to genital site.
In the absence of better data on the transmission po-
tential of extra-genital infections, any extra-genital STI
that remains untreated should be considered transmis-
sible. Given that there is a large number of extra-genital
CT and NG currently missed by the current standard of
care (i.e. untested, untreated or possibly sub-optimally
treated), the transmission potential of such infections
may be huge in women and in MSM. Infections at
extra-genital sites may impact the total STI burden in
the population by spread between sexual partners and
even between a woman’s anatomic sites. A recent math-
ematical study in MSM suggest that oral sex has an im-
portant role in sustaining NG in MSM by providing a
pool of untreated asymptomatic infection [79]. If extra-
genital CT and NG infections in women and MSM do
importantly help to sustain CT and NG endemicity, then
the gaps in their current management could help explain
why we do not see a decrease in CT and NG prevalence
from surveillance data in the face of greatly increased
genital testing and treating efforts [3, 4, 64].
Data on factors facilitating transmission are yet un-
available. It is for example unknown whether anorectal
and pharyngeal bacterial load is associated with an in-
creased risk for transmission, although such associations
may be biologically plausible. The CT and NG load de-
tected on pharyngeal or anorectal swabs load is generally
lower than on genital swabs [32, 60, 75, 80–82]. Never-
theless, only few studies have yet directly compared bac-
terial loads between anatomic sites. It is unknown what
are the transmission probabilities in relation to exposure,
i.e. after exposure by an alternate anatomic site or after
sex with an infected partner. A recent study among 51
women who reported anal sex and 90 MSM who re-
ported anal sex found similar mean numbers and ranges
in anorectal CT load [82]. This may suggest equal
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transmission probabilities in MSM and women reporting
anal sex. Future mathematical models and prospective
studies using multi-site sampling and measuring bacter-
ial load, and culture to detect viable bacteria could help
to obtain more insight in these aspects.
Missing extra-genital infections may also impact the
transmission of other STI. In MSM, it has been shown
that anorectal CT and NG facilitate HIV transmission
[83–85]. Analyses even support the idea of a causal ef-
fect of incident anorectal STI on HIV diagnosis [86].
Given the high prevalences of anorectal CT and NG in-
fections in MSM, it is not unreasonable to speculate that
they may have played an important role in driving the
HIV epidemic in these men. Therefore, anorectal CT
and NG testing is a potentially cost-effective and scalable
intervention to reduce HIV acquisition in high risk
MSM [87, 88]. In populations with lower HIV preva-
lence, such as women in industrialized countries, such
interventions may not be cost-effective. Yet, in women,
an association between anorectal infections and HIV,
whilst not yet studied, is plausible. This is because many
studies have shown that the presence of genital STI is
associated with increased HIV transmission in hetero-
sexuals, and women have unprotected anal sex and ano-
rectal STI, which are both acknowledged as important
risk factors for HIV acquisition in MSM.
Other extra-genital STI
As we have started to gain awareness of the occurrence
of extra-genital CT and NG in women, we have been
learning about other extra-genital STI as well. We know
that Mycoplasma genitalium (MG), Herpes Simplex
Virus, Human Papilloma Virus (HPV) and Trichomonas
vaginalis (TV) can be found at the anorectal site in a
woman. Presence at the anorectal site may be correlated
to their presence in the vagina, such as has been shown
for MG, TV and HPV [29, 89–91]. While some of these
pathogens are routinely tested for at the genital sites of
women, anorectal or pharyngeal testing of these STI is
rarely done in practice. It is also not recommended and
hampered when there are no available commercial as-
says (such as for MG). NAAT assays for the simultan-
eous detection of several anorectal infections ‘in one’ are
being developed, and that perhaps may pose interesting
future possibilities for combined extra-genital testing.
The gaps that are revealed in the management of extra-
genital CT and NG may also apply for these other STI.
Further, detecting the simultaneous presence of different
extra-genital pathogens will impact patient-management.
Summary and conclusion
Extra-genital CT and NG, and perhaps other STI such as
MG, may form a high potential for avoidable transmis-
sion and to some extent for avoidable morbidity in
MSM and in women. Extra-genital CT and NG can be
successfully detected using NAAT on simple to obtain
self-taken samples. Both men and women are willing to
test, and the so far hidden extra-genital STI epidemic
can be revealed. Strategies can be taken to increase the
reach of the testing and reduce costs by using internet
based programs, e-health strategies and home-collection.
Still several of the tests (NAAT testing on extra-genitally
taken samples) and strategies (home-collection) are not
FDA cleared. It is likely that, at least in the US, the
needed paradigm shift from a genital-centered approach
to testing (MSM and others at risk) to include a broader
sampling frame, will not become routine until FDA
clearance for extra-genital testing is obtained.
Testing should not solely be guided by indication of
symptoms or behavioral exposure as the large majority
of extra-genital STI are asymptomatic and over half of
the extra-genital infections occur in the absence of (re-
port of ) such symptoms or behavioural exposures in
both women and MSM. The majority of extra-genital in-
fections in MSM are single site infections that are not
being ‘inadvertently managed’ by treating urethral infec-
tions. Based on the current available data routine univer-
sal testing of all MSM instead of only testing MSM who
report symptoms or behavioural exposure is therefore an
imperative. To date, there is no evidence that the public
health impact, in terms of transmission, of anorectal or
pharyngeal infections is any different for women than it
is for MSM. However, in women, the clinical implica-
tions of extra-genital infections, and gains by testing
these, present uncertainties. In women, whether or not
to implement routine testing would depend on the in-
crement achieved in terms of avoided morbidity and fur-
ther spread. For some less prevalent STI, such as NG in
some countries, the increment is likely smaller in
women than MSM due to the more infrequent occur-
rence of these infections in women. For more prevalent
STI, such as CT and perhaps MG, the increment would
depend on the number extra-genital infections that
could be adequately managed (by treatment and part-
ner management) above the number of infections that
are already adequately managed by standard care for
the genital infection. We lack essential information in
several key area’s (summarized in Table 3) that need
to be addressed to fully understand the scope of im-
pact on public health and the clinical implications
posed by the occurrence of extra-genital STI in
women but also in MSM.
Future studies should address extra-genital and genital
morbidity caused by extra-genital infections. Random-
ized controlled trials are needed to determine whether
treatment efficacy for extra-genital infections differs
from that of genital infections. The full spectrum includ-
ing potential for further transmission of extra-genital
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infections to genital sites and related morbidity has not
yet been evaluated in women. Prospective studies in
couples or modeling studies could reveal more insight
on what are the transmission probabilities between part-
ners and between anatomic sites, and the associated fac-
tors. Morbidity and transmission may depend on the
extent the bacteria is able to replicate or presents in high
loads, which is unknown in MSM and in women. Stud-
ies using appropriate laboratory techniques, such as
quantitative PCR for measuring bacterial load, and cul-
ture to detect viable bacteria and antibiotic resistance, to
address these aspects are needed. These will greatly aid
our understanding of extra-genital infections and the dif-
ferences presented by these infections in MSM and
women. Finally, cost-effectiveness of extra-genital testing
has been evaluated for HIV infected MSM and was
shown cost-effective in case of anorectal CT and NG
[87, 88]. While it has been suggested that the lower
prevalence of NG in women overall makes it more costly
to screen for both CT and NG in women compared to
MSM [15], this is in practice not likely a valid argument
as most NAATs for CT are duplex assays also measuring
NG with the same costs.
Hidden extra-genital infections might fuel the trans-
mission of CT and NG and other STI and thereby in-
crease the overall STI burden. This may be very
important in the context of HIV and anorectal infection.
Health care providers should be aware of the common
occurrence of extra-genital infections. They should be
doing more and urgently need a better understanding,
especially in women, to obtain the highest gains of the
increased CT and NG testing and treating efforts. In-
creased testing is an imperative for MSM. There is much
to be learned to see if the same is true for women, and
possibly for some heterosexual men as well.
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